Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-19
2008-12-30
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
07470712
ABSTRACT:
The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1receptor activity.
REFERENCES:
patent: 4882342 (1989-11-01), von der Saal et al.
patent: 4954498 (1990-09-01), Mertens et al.
patent: 5322847 (1994-06-01), Marfat et al.
patent: 6492383 (2002-12-01), Munchhof et al.
patent: 2002/0016460 (2002-02-01), Snow et al.
patent: 2002/0132842 (2002-09-01), Hofmeister et al.
patent: 2003/0054298 (2003-03-01), Suzuki et al.
patent: 2004/0087626 (2004-05-01), Renhowe et al.
patent: 2005/0261244 (2005-11-01), Tuerdi et al.
patent: 2005/0267119 (2005-12-01), Chao et al.
patent: 2006/0173002 (2006-08-01), Sutton et al.
patent: 2006/0293522 (2006-12-01), Sutton
patent: 2007/0004677 (2007-01-01), Chao et al.
patent: 2133649 (1972-01-01), None
patent: 419210 (1991-02-01), None
patent: 1171904 (1969-11-01), None
patent: 2001199983 (2001-07-01), None
patent: WO 9808818 (1998-03-01), None
patent: WO 0005223 (2000-02-01), None
patent: WO 2003082272 (2003-10-01), None
patent: WO 2004094372 (2004-11-01), None
Vippagunta et al., “Crystalline solids”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Guillory, “Generation of Polymorphs, etc.,”in Brittain, ed. , “Polymorphism in Pharmaceutical Solids”, NY: Marcell Dekker, inc. , 1999, 183-226.
Abbracchio et al., “Purinoceptors: Are There Families of P2X and P2Y Purinoceptors?”, Pharmac. Ther., vol. 64, pp. 445-475, 1994.
Abbracchio et al., “Characterization of theUDP-glucose receptor (re-named here the P2Y14receptor) adds diversity to the P2Y family”, Trends in Pharmacological Sciences, vol. 24, No. 2, pp. 52-55, Feb. 2003.
Angelo et al., “N2-1H-Benzimidazol-2-yl-N4-phenyl-2,4-pyrimidinediamines and N2-1H-Benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-phenyl-2, 4-quinazolinediamines as Potential Antifilarial Agents”, J. Med. Chem, vol. 26, pp. 1311-1316, 1983.
Boeynaems et al., “Overview of P2Y Receptors as Therapeutic Targets”, Drug Development Research, vol. 52, pp. 187-189, 2001.
Burnstock et al., “P2 Purinergic Receptors: Modulation of Cell Function and Therapeutic Potential”, The Journal of Phamacology and Experimental Therapeutics, vol. 295, No. 3, pp. 862-869, 2000.
Chaudhari et al., “Synthesis and anthelmintic activity of new pyrido [3,2d] thiazoles”, Bulletin of Haffkine Institute, Haffkine Inst. Bombay, India, vol. 8 No. 3, pp. 87-92, 1980.
Daniel et al., “Molecular Basis for ADP-induced Platelet Activation”, The Journal of Biological Chemistry, vol. 273, No. 4, Issue of Jan. 23, pp. 2024-2029, 1998.
Fabre et al., “Decreased platelet aggregation increased bleeding time and resistance to thromboembolism in P2Y1-deficient rate”, Nature Medicine, vol. 5, No. 10, pp. 1199-1202, Oct. 1999.
Hechler et al., “The P2Y1receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel”, British Journal of Haematology, vol. 103, pp. 858-866, 1998.
Janssens et al., “Cloning and Tissue Distribution of the Human P2Y1Receptor”, Biochemical and Biophysical Research Communications, Article No. 0640, vol. 221, pp. 588-593, 1996.
Jin et al., “Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation”, Proc. Natl. Acad. Sci., vol. 95, pp. 8070-8074. 1998.
Kolodyazhnaya et al,. “Nitrogen-Containing Bisheterocyclic Systems”, Khimiya Geterotsikli. Soedin., vol. 6, No. 2, pp. 238-244, 1970.
Lenain, et al., “Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1receptor antagonist”, Journal of Thrombosis and Haemostasis, vol. 1, pp. 1144-1149, 2003.
Leon et al., “Key Role of the P2Y1Receptor in Tissue Factor-Induced Thrombin-Dependent Acute Thromboembolism Studies in P2Y1-Knockout Mice and Mice Treated with P2Y1 Antagonist”, Circulation, vol. 103, pp. 718-723, 2001.
Norenberg, et al., “Characterization and possible function of adenosine 5′-triphosphate receptors in activated rat microglia”, Br. J. Pharmacol., vol. 111, pp. 942-950, 1994.
Ochiai, et al., “New orally active PDE4 inhibitors with therapeutic potential”, Bioorganic & Medicinal Chemistry Letters, vol. 14, pp. 29-32, 2004.
Salter et al., “ATP Causes Release of Intracellular Ca2+via the Phospholipase Cβ/IP3Pathway in Astrocytes from the Dorsal Spinal Cord”, The Journal of Neuroscience, vol. 15(4), pp. 2961-2971, 1995.
Savi et al., “Role of P2Y1 purinoceptor in ADP-induced platelet activation”, FEBS Letters, vol. 422, pp. 291-295, 1998.
Simonov et al., “Heterylation of five-membered nitrogen-heterocycles by 1-methyl-2-chlorobenzimidazole”, Khim. Geterotsikl. Soedin., pp. 141-145, 1967, Abstract.
Baurand, A. et al., “The P2Y1Receptor as a Target for New Antithrombotic Drugs: A Review of the P2Y1Antagonist MRS-2179”, Cardiovascular Drug Reviews, vol. 21, pp. 67-76, 2003.
ACS Registry No. 771428-82-1.
ACS Registry No. 757895-09-3.
ACS Registry No. 749901-40-4.
ACS Registry No. 694452-42-1.
ACS Registry No. 327982-41-2.
U.S. Appl. No. 11/126,567, filed May 10, 2005, Tuerdi et al.
U.S. Appl. No. 11/126,915, filed May 10, 2005, Chao et al.
Das et al., “Discovery of 2-Amino-heteroaryl-benzothiazole-6-anilides as Potent p56Lck Inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 2587-2590, 2003.
U.S. Appl. No. 11/126,915, filed May 11, 2005, Chao et al.
Pande, A. et al., “Synthesis of 2-Arylaminobenzothiazoles and Aryl Isothiocyanates as Antitubercular Agents”, Indian Journal of Chemistry, vol. 22B, pp. 311-312 (1983).
Gungor Timur
Herpin Timothy F.
Lawrence R. Michael
Morton George C.
Poss Michael A.
Bristol--Myers Squibb Company
Miano Rosemary M.
Morris Patricia L
Sun Jing G.
LandOfFree
Amino-benzazoles as P2Y 1 receptor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino-benzazoles as P2Y 1 receptor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino-benzazoles as P2Y 1 receptor inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4026849